Abstract
Disease recurrence after local therapy for prostate cancer is increasingly common, most often with detectable or rising prostate-specific antigen (PSA) the earliest sign. Analysis of clinical and pathological factors can help determine which patients are at risk for treatment failure, while PSA characteristics and imaging studies can localize site of recurrent disease and identify men who may benefit from salvage therapy. Local treatment options include radiation therapy (external beam and brachytherapy) and cryoablation for patients who have undergone prostatectomy, and surgery, brachytherapy, and cryoablation for patients who have received radiotherapy. Novel treatment modalities are under investigation and may improve success of local salvage therapy while minimizing morbidity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meng, M., Carroll, P. Local therapy for prostate-specific antigen recurrence after definitive treatment. Prostate Cancer Prostatic Dis 4, 20–27 (2001). https://doi.org/10.1038/sj.pcan.4500497
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500497
Keywords
This article is cited by
-
Avoidance and management of positive surgical margins before, during and after radical prostatectomy
Prostate Cancer and Prostatic Diseases (2002)